Clinical Trials Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Mar 21, 2024; 30(11): 1545-1555
Published online Mar 21, 2024. doi: 10.3748/wjg.v30.i11.1545
Table 1 Patient data collected in the study in the intention-to-treat analysis
Item
Overall population
Placebo treatment
AN-PEP treatment
Number of patients402119
Age in yr, median (range)40.5 (29-47)42.0 (32-48)39.0 (28-46)
Females, n (%)33.0 (82.5)18.0 (85.7)15.0 (78.9)
CeD serology in U/mL, median (IQR)
IgA DGP at baseline3.0 (1.3-5.0)2.0 (1.0-5.0)4.0 (2.0-5.0)
End of study3 (2-6)3 (2-5)3 (2-6)
IgA tTG at baseline17 (7-44)10 (5-30)17 (8-49)
End of study12 (6-50)11 (6-15)17 (8-70)
SCI global score at randomization median score (IQR)36 (32-44)35 (30-44)40 (33-44)
End of the study median score (IQR)34 (28-40)32 (29-39)35 (28-41)
SCI scores > 38 at randomization, n (%)19 (47.5)8 (38.1)11 (57.9)
End of the study, n (%)12 (30.0)6 (28.6)6 (31.6)a
Stool GIP. Median and CI (IQR) of the average concentration for period (µg/g)
Run-in period0.37 (0-0.83)d0.34 (0-0.68)b0.42 (0-0.93)c
Treatment period0.21 (0-0.79)d0.19 (0.11-0.79)b0.22 (0-0.89)c
Table 2 Per-protocol data and analysis
Item
Overall population
Placebo treatment
AN-PEP treatment
Number of patients372017
Age in yr, median (range)40 (29-46)41 (31-48)39 (28-45)
Females, n (%)31 (83.8)17 (85.0)14 (82.3)
CeD serology in AU/mL, median (IQR)
IgA DGP at baseline3 (1-5)2 (1-5)3 (1-5)
At end of study3 (2-6)3 (2-5)3 (2-6)
IgA tTG at baseline17 (7-43)13 (6-36)17 (11-48)
End of study12 (6-48)11 (5-20)17 (7-62)
SCI global score at randomization median score (IQR)36.0 (31.0-44.0)35.0 (30.0-45.5)40.0 (33.0-44.0)
End of the study median score (IQR)33.0 (28.0-39.0)32.0 (28.5-37.5)35.0 (28.0-41.0)
SCI scores > 38 at randomization, n (%)17 (45.9)7 (35.0)10 (58.8)
End of study, n (%)10 (27.0)5 (25.0)5 (29.4)a
Stool GIP median and CI (IQR) of the average concentration for period, µg/g
Run-in period0.40 (0-0.86)0.37 (0-0.73)0.55 (0-0.93)
Treatment period0.30 (0.10-0.80)b0.25 (0.11-0.79)c0.32 (0-0.89)d
Table 3 Quality of life data from the Short Form-36 questionnaire on the intention-to-treat analysis
ItemPlacebo arm
AN-PEP arm
At baseline
Final
At baseline
Final
Number of patients2119
General health
Median score (IQR)65 (50-72)70 (50-80)b50 (35-75)50 (40-80)
Pain
Median score (IQR)80 (42-90)90 (50-80)b80 (45-90)67.5 (47.5-90.0)a
Vitality
Median score (IQR)60 (45-65)60 (50-70)40 (30-60)55 (40-65)c
Mental health
Median score (IQR)68 (52-72)68 (56-80)68 (40-72)64 (48-80)
Physical function
Median score (IQR)95 (75-100)95 (75-100)95 (85-100)100 (90-100)
Social function
Median score (IQR) 75 (50-100)100 (62.5-100.0)50 (37-100)75 (50-100)
Physical limitations
Median score (IQR)100 (50-100)100 (75-100)100 (25-100)75 (25-100)
Emotional limitations
Median score (IQR)50 (0-100)100 (66-100)b66.7 (0-100)66.7 (0-100)